Search
MM-093
go.drugbank.com/drugs/DB05512InvestigationalResearch on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults
Human Interleukin 8
go.drugbank.com/drugs/DB16456InvestigationalInterleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalA compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
Products: EUREA CREAMTerevalefim
go.drugbank.com/drugs/DB16397InvestigationalTerevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
ALKS 27
go.drugbank.com/drugs/DB05752ExperimentalALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).
Delorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIn addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.
International brands: ENProducts: ENCannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.